MannKind Corporation Share Price Nasdaq
Equities
US56400P2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
29/04 | MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment | MT |
29/04 | MannKind Gets FDA Clearance for Clofazimine IND Application | DJ |
Sales 2024 * | 260M 21.69B | Sales 2025 * | 313M 26.09B | Capitalization | 1.15B 96.23B |
---|---|---|---|---|---|
Net income 2024 * | 38M 3.17B | Net income 2025 * | 73M 6.09B | EV / Sales 2024 * | 3.48 x |
Net cash position 2024 * | 248M 20.72B | Net cash position 2025 * | 273M 22.75B | EV / Sales 2025 * | 2.82 x |
P/E ratio 2024 * |
32.3
x | P/E ratio 2025 * |
18.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.47% |
Latest transcript on MannKind Corporation
Managers | Title | Age | Since |
---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 47 | 14/16/14 |
Sanjay Singh
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/22/01 |
Kevin Kaiserman
CTO | Chief Tech/Sci/R&D Officer | - | 31/20/31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 27/18/27 | |
Anthony Hooper
BRD | Director/Board Member | 69 | 01/20/01 |
Ronald Consiglio
BRD | Director/Board Member | 80 | 01/03/01 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |